导读 本周四川、浙江 等 地均有母基金宣布落地或出资，母基金重点布局 先进制造、 高端装备、新能源、新材料 等领域 。此外，多地母基金扩资百亿， 赋能本地先进产业。 值得关注的是，本周福建 社保科创基金 通过中基协备案 ，基金规模 200亿元， 重点围绕 人工智能、高端制造、新能源 等领域布局。此外， 经开 科创母基金完成 国内首支S基金投资。 基金设立层面，北京、上海、山东等地均有基金宣布设立或落 地，基金主要聚焦人工智能、集成电路 、未来智造、生命健康、新能源 等领域 。山 东30亿元新动能未来产业基金主攻前沿制造，江苏5 0亿"人工智能+"行动专项基金 瞄准AI赛道。此外， 总规模20亿元的烟台市新城发展创投基金布 局数字、服务、绿色经济。 横琴引导基金扩募至300亿 近日，经合作区执委会批准横琴粤澳深度合作区产业投资基金（以下简称"引导基金"）总规模由100亿提升至300亿。 据悉，本次扩募将进一步提升引导基金，在以投促引、推动合作区"四新"产业发展与中葡经贸中心建设方面的效能，更好服务澳门经济适度多元发 展。 自2023年8月成立以来，在合作区执委会和引导基金办公室指导下，引导基金始终坚守服务合作区 ...

Core Viewpoint - Junshi Biosciences is positioned as a leading innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on first-in-class and best-in-class drug development [2] Group 1: Company Overview - Junshi Biosciences was established on December 27, 2012, and went public on July 15, 2020, specializing in the research and commercialization of monoclonal antibody drugs and other therapeutic proteins [7] - The company's main revenue sources include drug sales (90.67%), technology licensing (8.74%), and technical services (0.59%) [7] - As of September 30, 2023, Junshi Biosciences reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, and a net profit attributable to shareholders of -596 million yuan, a year-on-year increase of 35.72% [8] Group 2: Product Development and Pipeline - The company has developed a significant product portfolio, including the first domestically approved PD-1 monoclonal antibody, Toripalimab, which has received approval for 11 indications in mainland China and is also approved in multiple countries including the US and EU [2] - Junshi Biosciences is also developing Tifcemalimab, the world's first anti-BTLA monoclonal antibody entering clinical development, with ongoing Phase III trials and several combination studies with Toripalimab [2] - The company is collaborating with various research institutions to develop a monkeypox recombinant protein vaccine, currently in preclinical development [3] Group 3: Market Activity - On January 9, 2024, Junshi Biosciences' stock rose by 4.09%, with a trading volume of 520 million yuan and a market capitalization of 40.246 billion yuan [1] - The stock has seen a net inflow of 42.43 million yuan from major investors, indicating a mixed trend in investor sentiment [4][5] - The average trading cost of the stock is 39.88 yuan, with the current price approaching a resistance level of 39.67 yuan, suggesting potential for upward movement if this level is surpassed [6]

1月9日，康华生物（维权）盘中上涨2.03%，截至14:00，报75.50元/股，成交1.60亿元，换手率1.83%， 总市值98.11亿元。 资金流向方面，主力资金净流出1036.66万元，特大单买入1331.02万元，占比8.30%，卖出2413.70万 元，占比15.04%；大单买入4601.70万元，占比28.68%，卖出4555.67万元，占比28.40%。 分红方面，康华生物A股上市后累计派现6.86亿元。近三年，累计派现4.62亿元。 机构持仓方面，截止2025年9月30日，康华生物十大流通股东中，香港中央结算有限公司位居第五大流 通股东，持股118.26万股，为新进股东。南方中证1000ETF（512100）位居第七大流通股东，持股85.06 万股，相比上期减少1.11万股。华夏行业景气混合A（003567）退出十大流通股东之列。 责任编辑：小浪快报 资料显示，成都康华生物制品股份有限公司位于四川省成都经济技术开发区北京路182号，成立日期 2004年4月2日，上市日期2020年6月16日，公司主营业务涉及疫苗的综合性研究、开发、经营。主营业 务收入构成为：非免疫规划疫苗99.99%，其他0. ...

1月9日，贝达药业盘中上涨2.00%，截至13:21，报50.38元/股，成交2.89亿元，换手率1.38%，总市值 211.97亿元。 资金流向方面，主力资金净流出934.89万元，特大单买入899.98万元，占比3.12%，卖出1857.60万元， 占比6.43%；大单买入6347.36万元，占比21.98%，卖出6324.63万元，占比21.90%。 贝达药业今年以来股价涨7.90%，近5个交易日涨7.90%，近20日涨3.64%，近60日跌12.97%。 机构持仓方面，截止2025年9月30日，贝达药业十大流通股东中，兴全商业模式混合(LOF)A（163415） 位居第五大流通股东，持股582.70万股，为新进股东。易方达创业板ETF（159915）位居第六大流通股 东，持股545.55万股，相比上期减少91.23万股。兴全合润混合A（163406）位居第七大流通股东，持股 540.17万股，为新进股东。中欧医疗健康混合A（003095）、南方中证500ETF（510500）退出十大流通 股东之列。 责任编辑：小浪快报 贝达药业所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：眼科概念、 ...

Group 1 - The core viewpoint of the news is that Baiotai's stock has shown a significant increase in price and trading activity, indicating positive market sentiment despite some fluctuations in recent months [1][2]. - As of January 9, Baiotai's stock price rose by 2.03% to 25.08 CNY per share, with a total market capitalization of 10.385 billion CNY [1]. - The company has experienced an 8.38% increase in stock price year-to-date, with a 5.82% increase over the past 20 days, although it has seen a 7.11% decline over the last 60 days [2]. Group 2 - Baiotai's main business involves the research and production of innovative drugs and biosimilars, with 91.90% of its revenue coming from drug sales [2]. - As of September 30, 2025, Baiotai reported a revenue of 684 million CNY, reflecting a year-on-year growth of 17.57%, while the net profit attributable to shareholders was -224 million CNY, showing a 38.72% increase in losses compared to the previous year [2]. - The company is categorized under the pharmaceutical and biotechnology industry, specifically in the bioproducts sector, and is involved in various concepts such as biomedicine and cancer treatment [2].

Core Viewpoint - Guangshentang's stock price has shown fluctuations, with a recent increase of 2.04% on January 9, 2025, while facing significant challenges in revenue and profit margins [1][2]. Group 1: Stock Performance - As of January 9, 2025, Guangshentang's stock price reached 92.93 CNY per share, with a trading volume of 4.25 billion CNY and a turnover rate of 3.44%, resulting in a total market capitalization of 14.801 billion CNY [1]. - Year-to-date, Guangshentang's stock has increased by 4.24%, with a 4.24% rise over the last five trading days, a 1.40% increase over the last 20 days, and a decline of 22.56% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Guangshentang reported a revenue of 316 million CNY, reflecting a year-on-year decrease of 3.21%, while the net profit attributable to shareholders was -112 million CNY, a significant decline of 57.96% year-on-year [2]. - The company has not distributed any dividends in the last three years, with a total payout of 84.6485 million CNY since its A-share listing [3]. Group 3: Shareholder Information - As of September 30, 2025, Guangshentang had 45,800 shareholders, an increase of 125.95% from the previous period, with an average of 2,985 circulating shares per shareholder, down by 55.74% [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the seventh largest with 1.7463 million shares, while the China Europe Medical Health Mixed A fund has reduced its holdings by 1.1365 million shares, now holding 708,100 shares [3].

Core Viewpoint - Kanghong Pharmaceutical has shown a positive stock performance with a year-to-date increase of 13.65% and a market capitalization of 31.38 billion yuan as of January 9 [1]. Financial Performance - For the period from January to September 2025, Kanghong Pharmaceutical achieved a revenue of 3.624 billion yuan, representing a year-on-year growth of 6.23%. The net profit attributable to shareholders was 1.033 billion yuan, with a year-on-year increase of 6.08% [2]. Shareholder Information - As of December 31, the number of shareholders for Kanghong Pharmaceutical reached 28,900, an increase of 1.32% from the previous period. The average number of circulating shares per shareholder decreased by 1.30% to 23,805 shares [2]. Dividend Distribution - Since its A-share listing, Kanghong Pharmaceutical has distributed a total of 2.038 billion yuan in dividends, with 1.04 billion yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, the fourth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 28.007 million shares, an increase of 730,000 shares from the previous period. Other notable shareholders include Dachen Rui Xiang Mixed A and Dachen Competitive Advantage Mixed A, which saw reductions in their holdings [3].

Group 1 - The core viewpoint of the news is that Shuyou Shen's stock has shown a significant increase in price recently, with a year-to-date increase of 10.65% and a notable rise of 10.65% over the last five trading days [1] - As of January 9, Shuyou Shen's stock price reached 30.23 yuan per share, with a total market capitalization of 14.443 billion yuan [1] - The company primarily engages in the research, production, and sales of biological products and certain chemical drugs, with its main revenue sources being the injection of mouse nerve growth factor (59.17%) and compound polyethylene glycol electrolyte powder (33.19%) [1] Group 2 - As of September 30, the number of shareholders for Shuyou Shen increased by 46.97% to 46,500, while the average circulating shares per person decreased by 31.98% to 9,745 shares [2] - For the period from January to September 2025, Shuyou Shen reported a revenue of 181 million yuan, a year-on-year decrease of 30.82%, and a net profit attributable to shareholders of -30.69 million yuan, a decrease of 227.71% [2] - The company has distributed a total of 771 million yuan in dividends since its A-share listing, but has not paid any dividends in the last three years [3]

资金流向方面，主力资金净流出6118.14万元，特大单买入1805.52万元，占比5.50%，卖出8921.42万 元，占比27.18%；大单买入8236.94万元，占比25.09%，卖出7239.18万元，占比22.05%。 福斯特今年以来股价涨0.21%，近5个交易日涨0.21%，近20日涨1.16%，近60日跌13.00%。 资料显示，杭州福斯特应用材料股份有限公司位于浙江省杭州市临安区锦北街道福斯特街8号，成立日 期2003年5月12日，上市日期2014年9月5日，公司主营业务涉及太阳能电池胶膜、共聚酰胺丝网状热熔 胶膜、太阳能电池背板等产品的研发、生产和销售。主营业务收入构成为：光伏胶膜90.65%，感光干 膜4.08%，光伏背板2.20%，其他1.25%，铝塑膜0.81%，其他(补充)0.71%，太阳能发电系统0.30%。 1月9日，福斯特盘中下跌2.03%，截至13:02，报13.99元/股，成交3.28亿元，换手率0.89%，总市值 364.96亿元。 机构持仓方面，截止2025年9月30日，福斯特十大流通股东中，香港中央结算有限公司位居第三大流通 股东，持股7046.50万股，相比上期减少2 ...

Group 1 - The core viewpoint of the news is that Aolian Electronics has shown a significant increase in stock price and trading activity, indicating positive market sentiment [1][2] - As of January 9, Aolian Electronics' stock price increased by 2.08% to 19.65 CNY per share, with a total market capitalization of 3.362 billion CNY [1] - The company has experienced a year-to-date stock price increase of 10.46%, with a 13.26% increase over the past 60 days [2] Group 2 - Aolian Electronics specializes in the research, production, and sales of automotive electronic and electrical components, with major revenue contributions from electronic throttle assemblies (37.46%), interior rearview mirror assemblies (33.09%), and gear shift controllers (29.17%) [2] - The company reported a revenue of 324 million CNY for the period from January to September 2025, reflecting a year-on-year growth of 1.08%, while net profit attributable to shareholders reached 3.3287 million CNY, a significant increase of 235.88% [2] - Aolian Electronics has distributed a total of 70.3423 million CNY in dividends since its A-share listing, with 5.9889 million CNY distributed over the past three years [3]